Last updated on August 5, 2026 · Originally published April 7, 2017
Every terpene in cannabis has a story attached, and humulene’s is that it makes you less hungry. It is on dispensary menus, in strain descriptions, in most articles written about the compound. It is the single most repeated thing anyone says about it.
But there are no controlled human studies showing it does anything of the kind.
It is not that anyone has disproved it. The claim appears to have come from nowhere in particular and stuck around, crowding out everything genuinely interesting about humulene ever since.
The twin that didn’t get CB2
Humulene’s other name is alpha-caryophyllene, and that is the most useful fact about it.
Beta-caryophyllene is the best-established terpene agonist at CB2 — the one people call a dietary cannabinoid. Humulene has the same molecular formula, C₁₅H₂₄, but its fifteen carbons connect differently. Beta-caryophyllene forms a nine-membered ring fused to a four-carbon cyclobutane. Humulene forms a single eleven-membered ring, with no cyclobutane at all.
That change in ring structure appears to be decisive for their very different CB2 pharmacology. Beta-caryophyllene activates CB2 selectively and reproducibly. In the classic 2008 binding study, humulene did not meaningfully interact with that receptor.
The safer conclusion is not that humulene has no cannabinoid-receptor activity at all — later work using different expression systems has reported weak activation across a broad panel of terpenes, humulene included. It is that humulene does not share beta-caryophyllene’s well-characterised CB2 pharmacology, despite being built from the same atoms.
That is the point worth taking away: a shared biosynthetic origin does not give terpenes shared pharmacology. A different ring structure can mean very different behaviour at a human receptor.
Molecular formula: C₁₅H₂₄ Molecular mass: 204.36 g/mol
The hops behind humulene
Humulene is named after Humulus lupulus — hops — where it was first identified, and it can account for a substantial share of hop essential oil.
But the aroma you actually smell in beer is not quite humulene. Much of what goes into the boil is lost or transformed before the beer reaches the glass, and its oxidation products — epoxides among them — rather than humulene alone help produce the traditional kettle-hop character. Dry hopping, which adds hops after the boil, changes the picture again.
Hops and cannabis both belong to the family Cannabaceae, and some cultivars share enough of the same volatile compounds to smell faintly hoppy. Those compounds are not exclusive to the family, however: humulene occurs widely across the plant kingdom, turning up in sage, clove, ginseng, coriander, black pepper and balsam fir. In cannabis it is a common constituent, usually a minor one, and frequently listed on certificates of analysis directly beside beta-caryophyllene, which is how the two get confused in the first place.
What the research actually supports
The honest summary is that humulene has a modest but real preclinical literature, almost all of it about inflammation.
The most-cited work comes from Brazilian groups studying Cordia verbenacea, whose essential oil contains both alpha-humulene and trans-caryophyllene. A 2007 study found anti-inflammatory effects comparable to dexamethasone in its model, and follow-up work in 2009 examined airway allergic inflammation. Separate research on balsam fir oil reported antitumour activity in cell culture, apparently through the generation of reactive oxygen species leading to apoptosis. That last finding is often quoted on cannabis sites without the words “in cell culture,” which changes it considerably.
The most useful recent result is more direct. A 2025 study tested four cannabis terpenes against mouse models of post-operative and fibromyalgia pain. Geraniol produced the strongest effect, with linalool and alpha-humulene next, and blocking the adenosine A2A receptor blocked the response. That is a mechanism with nothing to do with cannabinoid receptors, and it provides unusually direct evidence that humulene can act on its own.
Humulene has also appeared in experiments testing the entourage hypothesis, with results that depend heavily on the assay. Two frequently cited studies found it did not modulate THC’s activity at human CB1 or CB2 receptors, and did not modulate cannabinoid activity at TRPA1 or TRPV1 channels. Later work using a different receptor-expression system has reported direct and combined effects for a range of cannabis terpenes — but humulene has not emerged as one of the clearer examples, and some of those measurements were constrained by how poorly it dissolves at the concentrations tested.
The defensible conclusion is narrower than either camp usually states it: there is no convincing evidence that humulene meaningfully changes what THC does in people.
There is one more piece worth mentioning carefully. A 2026 study of a sesquiterpene-rich cannabis essential oil reduced neuroinflammation and improved motor recovery in a multiple sclerosis model, and humulene was among the three dominant constituents alongside beta-caryophyllene and caryophyllene oxide. Blocking CB2 abolished the benefit. Beta-caryophyllene is the obvious candidate for a CB2-dependent effect — but the study tested the complete oil rather than its constituents separately, so it cannot establish which compound, or which combination, was responsible.
Where the appetite story came from
The origin of the appetite claim is difficult to reconstruct, which is itself telling.
The claim appears in aromatherapy and cannabis literature as an established property, rarely with a primary study attached. It shows up formalised in widely-copied bullet lists describing humulene as “anorectic,” and from there enters dispensary menus and strain descriptions as settled fact. There are no clinical trials. We could not identify a convincing animal study in which isolated humulene was tested specifically for its effect on food intake.
What makes it stick is probably that it is a satisfying story. THC increases appetite, famously. A terpene that does the opposite makes a neat counterweight, and it gives a compound whose real science is complicated and preliminary a simple identity people can remember. Whether it was ever demonstrated seems not to have come up.
If you want a cannabis compound with genuine appetite research behind it, THCV is the one to look at, and even there the human evidence is thinner than the headlines.
What humulene actually contributes
Humulene’s clearest contribution is aroma, and that is not a small thing.
It contributes the woody, earthy, faintly bitter note that shows up in hoppy cultivars. Because it is a sesquiterpene, humulene is heavier and less volatile than monoterpenes such as myrcene and limonene, so it may be retained more readily through some forms of drying and processing — though heat and oxidation can still remove or transform it, and decarboxylation takes its share. How much it contributes to the finished aroma depends not only on how much survives, but also on its oxidation products and sensory threshold.
The therapeutic picture is genuinely open. The anti-inflammatory findings point in a reasonably consistent direction, the A2A result is interesting, and neither has been tested in people. Search the research databases for humulene and you mostly find it listed as a constituent in analyses of something else, rather than studied for itself. That absence is informative.
It is a real compound with a real aroma and a modest body of preclinical evidence. There is no good evidence that it suppresses appetite, and the confidence with which that gets repeated should make you wonder what else on the same menu was written the same way.
For the wider context, see our guide to cannabis terpenes — and for the beer end of the story, our piece on hops, humulene and the brewery.
——————————————————————————————————————————————————
Updated August 5, 2026. This article was substantially rewritten and expanded. The unsupported claim that humulene suppresses appetite has been re-examined, the account of its contribution to hop aroma has been corrected, and new material covers its relationship to beta-caryophyllene, the adenosine A2A findings and the latest entourage experiments.
Research for this article was compiled using DeepWeed, T&T’s cannabis research database — explore the underlying studies there.
Photo: Pexels, Ahmed Hamed.
Sources
- Fernandes ES, Passos GF, Medeiros R, et al. Anti-inflammatory effects of compounds alpha-humulene and (−)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Eur J Pharmacol. 2007;569(3):228–236
- Rogerio AP, Andrade EL, Leite DFP, Figueiredo CP, Calixto JB. Preventive and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation. Br J Pharmacol. 2009;158(4):1074–1087
- Legault J, Dahl W, Debiton E, Pichette A, Madelmont J-C. Antitumor activity of balsam fir oil: production of reactive oxygen species induced by α-humulene as possible mechanism of action. Planta Med. 2003;69(5):402–407. doi:10.1055/s-2003-39695
- Legault J, Pichette A. Potentiating effect of β-caryophyllene on anticancer activity of α-humulene, isocaryophyllene and paclitaxel. J Pharm Pharmacol. 2007;59(12):1643–1647
- Booth JK, Page JE, Bohlmann J. Terpene synthases from Cannabis sativa. PLoS ONE. 2017;12(3):e0173911. doi:10.1371/journal.pone.0173911
- Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M. Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors. Cannabis Cannabinoid Res. 2019;4(3):165–176. doi:10.1089/can.2019.0016
- Heblinski M, Santiago M, Fletcher C, et al. Terpenoids commonly found in Cannabis sativa do not modulate the actions of phytocannabinoids or endocannabinoids on TRPA1 and TRPV1 channels. Cannabis Cannabinoid Res. 2020;5(4):305–317. doi:10.1089/can.2019.0099
- Raz N, Eyal AM, Zeitouni DB, Hen-Shoval D, Davidson EM, Danieli A, Tauber M, Ben-Chaim Y. Selected cannabis terpenes synergize with THC to produce increased CB1 receptor activation. Biochem Pharmacol. 2023;212:115548. doi:10.1016/j.bcp.2023.115548
- Raz N, Eyal AM, Fahoum-Khalefa N, Tauber M, Ben-Chaim Y. Selective activation of cannabinoid receptors by cannabis terpenes. Biochem Pharmacol. 2026;243(Pt 1):117498. doi:10.1016/j.bcp.2025.117498. Epub 2025 Oct 30
- Raz N, Eyal AM, Fahoum-Khalefa N, Tauber M, Schurr N, Ben-Chaim Y. Synergistic and additive terpene–THC interactions in cannabinoid CB1 and CB2 receptors. Biochem Pharmacol. 2026;251(Pt 2):118185. doi:10.1016/j.bcp.2026.118185
- Seekins CA, Welborn AM, Schwarz AM, Streicher JM. Select terpenes from Cannabis sativa are antinociceptive in mouse models of post-operative pain and fibromyalgia via adenosine A2A receptors. Pharmacol Rep. 2025;77(1):172–181. doi:10.1007/s43440-024-00687-1
- A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in an experimental autoimmune encephalomyelitis model through CB2-mediated signalling. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158068
